Hansen Medical to Exhibit Its Magellan(TM) Robotic System at 35th Annual Charing Cross International Symposium

Hansen Medical to Exhibit Its Magellan(TM) Robotic System at 35th Annual 
Charing Cross International Symposium 
Magellan(TM) Robotic System to Be Featured in Multiple Presentations
and Company to Host Joint Symposium With Philips 
MOUNTAIN VIEW, CA -- (Marketwire) -- 04/01/13 --  Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced it will showcase its Magellan(TM) Robotic System at the
35th Annual Charing Cross International Symposium from April 6-9 in
London. The Company will be exhibiting the Magellan Robotic System at
Booth 628. 
In addition, Professor Nick Cheshire, MD of St. Mary's Hospital, part
of the Imperial College Healthcare NHS Trust in London, and Barry
Katzen, MD, founder and Medical Director of the Baptist Cardiac &
Vascular Institute (Baptist Hospital of Miami), will participate in a
panel discussion titled, "Great Debate: Influence of Robotics and
Simulators," during the "Carotid Challenges" session at 10:00 am on
Tuesday, April 9.  
Hansen Medical will also be co-sponsoring a symposium with Philips
Healthcare from 12:30 pm-3:30 pm on Monday, April 8 in the Green
Learning Center, titled "Advanced Imaging in the Hybrid Operating
Room." This symposium will feature Dr. Katzen who will discuss his
clinical experiences with the Magellan System in a variety of
interventional procedures. 
Lastly, on Sunday, April 7 at 4:45 pm Professor Jean-Pierre
Becquemin, MD of Creteil, France will present on his experiences with
the Magellan System in a presentation titled, "Early Experiences with
Intravascular Robotics." 
"We are pleased that our Magellan Robotic System will be highlighted
at Charing Cross, Europe's longest running and leading vascular
symposium," said Bruce Barclay, President and CEO of Hansen Medical.
"The presentations featuring our technology will provide additional
opportunities for clinicians to better understand the significant
clinical and economic benefits, and real world medical utility,
provided by the Magellan System. We are also excited to be co-hosting
a symposium with our partner Philips for the second consecutive year.
Since commencing the initial U.S. launch of the Magellan System last
June, we have generated a large and growing pipeline of clinical
interest in our robotic t
echnology, and we look forward to further
building on this momentum at Charing Cross." 
"At St. Mary's, we have performed a breadth of complex endovascular
procedures with the Magellan Robotic System in the past year," said
Professor Cheshire. "Charing Cross, being the premier European
endovascular event, affords us the opportunity to discuss the
clinical benefits we're seeing through the implementation of
intravascular robotics." 
About the Magellan(TM) Robotic System 
Hansen Medical's Magellan Robotic System is based upon the flexible
robotic technology incorporated in the Sensei-X(R) Robotic Catheter
System currently sold in the U.S. and Europe, which has been used in
excess of 10,000 patients, but includes a number of key enhancements.
In particular, the Magellan Robotic System: 

--  Provides solid catheter stability for placement of therapeutic
--  Is designed to enable predictable procedure times and increased case
--  Allows for independent, individual robotic control of the distal tips
    of both the outer sheath and the inner leader catheter, as well as
    robotic manipulation of standard guidewires.
--  Is designed to allow for sufficient extension inside the body to
    access hard to reach peripheral anatomy.
--  Preserves the open architecture featured in the Sensei System to allow
    for the subsequent use of many 6F therapeutic devices on the market
--  Is designed to potentially reduce physician radiation exposure and
    fatigue by employing a remote physician workstation.

About Hansen Medical, Inc.  
Hansen Medical, Inc., based in Mountain View, California, is the
global leader in intravascular robotics, developing products and
technology designed to enable the accurate positioning, manipulation
and control of catheters and catheter-based technologies. The
Company's Magellan(TM) Robotic System, NorthStar(TM) Robotic Catheter
and related accessories, which are intended to facilitate navigation
to anatomical targets in the peripheral vasculature and subsequently
provide a conduit for manual placement of therapeutic devices, have
undergone both CE marking and 510(k) clearance and are commercially
available in the European Union, and the U.S. In the European Union,
the Company's Sensei(R) X Robotic Catheter System and Artisan Control
Catheter are cleared for use during electrophysiology (EP)
procedures, such as guiding catheters in the treatment of atrial
fibrillation (AF), and the Lynx(R) Robotic Ablation Catheter is
cleared for the treatment of AF. This robotic catheter system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S. the Company's Sensei X Robotic
Catheter System and Artisan Control Catheter were cleared by the U.S.
Food and Drug Administration for manipulation and control of certain
mapping catheters in EP procedures. In the United States, the Sensei
System is not approved for use in guiding ablation procedures; this
use remains experimental. The U.S. product labeling therefore
provides that the safety and effectiveness of the Sensei X System and
Artisan Control Catheter for use with cardiac ablation catheters in
the treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
Forward-Looking Statements  
This press release contains forward-looking statements regarding,
among other things, statements relating to goals, plans, objectives,
milestones and future events. All statements, other than statements
of historical fact, are statements that could be deemed
forward-looking statements, including statements containing the words
"plan," "expects," "potential," "believes," "goal," "estimate,"
"anticipates," and similar words. These statements are based on the
current estimates and assumptions of our management as of the date of
this press release and are subject to risks, uncertainties, changes
in circumstances and other factors that may cause actual results to
differ materially from the information expressed or implied by
forward-looking statements made in this press release. Examples of
such statements include statements about the potential benefits of
our Magellan Robotic Sy
stem for hospitals, patients and physicians,
expectations of shipments and installations of our robotic systems,
catheter sales, and procedures, expectations of gross margins and
operating expenses for 2013, the sufficiency of the company's cash
resources for supporting the Company's operations, expected
efficiencies from cost saving initiatives, and the anticipated timing
of commercially launching a 6F vascular catheter. Important factors
that could cause actual results to differ materially from those
indicated by such forward-looking statements include, among others:
engineering, regulatory, manufacturing, sales and customer service
challenges in developing new products and entering new markets; the
commercial viability of our products in the vascular markets;
potential safety and regulatory issues that could slow or suspend our
sales; the effect of economic conditions on capital spending by our
potential customers; the uncertain timelines for the sales cycle for
newly introduced products; the rate of adoption of our systems and
the rate of use of our catheters; the scope and validity of
intellectual property rights applicable to our products; competition
from other companies; our ability to recruit and retain key
personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Annual Report on Form 10-K for
the year ended December 31, 2012 filed with the SEC on March 18, 2013
and the risks discussed in our other reports filed with the SEC.
Given these uncertainties, you should not place undue reliance on the
forward-looking statements in this press release. We undertake no
obligation to revise or update information herein to reflect events
or circumstances in the future, even if new information becomes
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries. 
Investor Contacts:
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc. 
FTI Consulting, Inc.
Brian Ritchie
John Capodanno
Press spacebar to pause and continue. Press esc to stop.